The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study Results With Cytos Biotechnology AG’s CYT003 for the Treatment of Allergic Asthma
3/13/2013 9:34:58 AM
Cytos Biotechnology Ltd (SIX:CYTN) today announced the publication of the results from its phase 2a clinical trial with CYT003-QbG10 (CYT003), a first-in-class immune modulator in clinical development as a potential new treatment for allergic asthma. The data are published in the March issue of The Journal of Allergy and Clinical Immunology (JACI) in the article entitled “The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma” by Kai-Michael Beeh , MD, et al. (J Allergy Clin Immunol. 2013 Mar;131(3):866-874).
comments powered by